◆ NeutralCORGMEDVCYTWST

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Zacks Investment Research·
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

Read Full Article at Zacks Investment Research
← Back to Financial Intelligence